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BACKGROUND: Human breast carcinoma cells secrete an adenosine 50-diphosphate transphosphorylase (sNDPK) known to induce
endothelial cell tubulogenesis in a P2Y receptor-dependent manner. We examined sNDPK secretion and its effects on human
endothelial cells.
METHODS: Nucleoside diphosphate kinase (NDPK) secretion was measured by western blot and enzyme-linked immunosorbent assay,
while transphosphorylase activity was measured using the luciferin-luciferase ATP assay. Activation of MAPK was determined by
western blot analysis, immunofluorescence and endothelial cell proliferation and migration.
RESULTS: A panel of breast cancer cell lines with origin as ductal carcinoma, adenocarcinoma or medullary carcinoma, secrete sNDPK-
A/B. Addition of purified NDPK-B to endothelial cultures activated VEGFR-2 and Erk1/2, both of which were blocked by inhibitors of
NDPK and P2Y receptors. Activation of VEGFR-2 and ErK1/2 by 2-methylthio-ATP (2MeS-ATP) was blocked by pretreatment with
the P2Y1-specific antagonist MRS2179, the proto-oncogene non-receptor tyrosine kinase (Src) inhibitor PP2 or the VEGFR-2
antagonist SU1498. Nucleoside diphosphate kinase-B stimulates cell growth and migration in a concentration-dependent manner
comparable to the effect of vascular endothelial growth factor. Treatment of endothelial cells with either NDPK-B or 2MeS-ATP
induced migration, blocked by P2Y1, Src or VEGFR-2 antagonists.
CONCLUSION: sNDPK supports angiogenesis. Understanding the mechanism of action of sNDPK and P2Y1 nucleotide signalling in
metastasis and angiogenesis represent new therapeutic targets for anti-angiogenic therapies to benefit patients.
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Vascular P2 nucleotide receptors activated by ATP include both
ligand-gated ion channels (P2X) and hetero-trimeric G protein-
coupled (P2Y) receptors (White and Burnstock, 2006). P2Y
receptors are recognised as important regulators of carcinogenesis
and endothelial regulation and are integral modulators of platelet
aggregation and blood flow regulation (Buxton et al, 2001;
Burnstock, 2006; White and Burnstock, 2006). Extracellular ATP
activates P2Y receptors on vascular endothelial cells to release
vasoactive mediators such as nitric oxide, prostacyclin and
additional ATP (Yang et al, 1994; Buxton et al, 2001), which elicit
vasodilation and propagate this effect downstream (Buxton et al,
2001; Kashiwagi et al, 2005). We have proposed that breast tumour
cells that secrete nucleoside diphosphate kinase (NDPK) promote
their intravasation and extravasation from blood vessels by
generating nucleotides to activate P2Y receptors on endothelium.
Furthermore, we and others (Seye et al, 2004; Rumjahn et al, 2009)
have shown that P2Y1/2 receptors activated by extracellular ATP
transactivate VEGFR-2, demonstrating a direct link between
extracellular nucleotide regulation and the VEGFR-2 signalling
cascade in the service of angiogenesis.
Nucleoside diphosphate kinase domains are present in a large
family of structurally and functionally conserved proteins from
bacteria to humans. There are eight isoforms of this plurifunc-
tional protein, NM23-H1-H8 (McDermott et al, 2008). NM23-H1
and NM23-H2 (NDPK-A and NDPK-B) are the most abundant and
have significant roles in normal and diseased sates (Postel, 1998;
Hartsough and Steeg, 2000). In non-transformed cells, NDPK
functions as an NDPK regenerating ATP levels for intracellular
‘housekeeping’ enzymes by covalently transferring the g-phosphate
from a nucleoside triphosphate (NTP) such as GTP to a nucleoside
diphosphate acceptor (NDP; e.g., ADP). Nucleoside diphosphate
kinase has also been shown to act as a histidine kinase,
transcription activator and an exonuclease (Postel, 2003). NM23
was originally described as non-metastatic gene 23, which was
found in mouse carcinoma cells and was thought to be inversely
related to metastasis (Postel, 2003; Palmieri et al, 2006) although
this has been controversial. There is evidence to support an
intracellular role for NM23/NDPK in tumour metastasis (Hamby
et al, 2000; Roymans et al, 2002), and high tissue levels of NDPK-A
protein have been found in patients with breast carcinoma
(Heimann et al, 1998; Sauer et al, 1998). Nucleoside diphosphate
kinases are secreted by various solid and haematological
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smalignancies (Anzinger et al, 2001; Niitsu et al, 2001; Okabe-Kado
et al, 2005a) and promote growth of acute myelogenous leukaemia
cells (Okabe-Kado et al, 2009b) and endothelial cells in vitro
(Rumjahn et al, 2007). Extracellular NDPK activity regulates
extracellular nucleotide levels on the cell surface in many cell types
(Yang et al, 1994; Lazarowski et al, 2000; Spychala et al, 2004). We
have shown that membrane bound ecto-NDPK acts extracellularly
to contribute to the maintenance of vascular tone regulating blood
flow via nucleotide receptor activation (Buxton et al, 2001).
Nucleoside diphosphate kinase regulation of blood flow first leads
us to propose a pathological role for secreted NDPK (sNDPK) in
cancer and tumour angiogenesis.
Here, we tested the notion that breast cancer cell lines, known to
be metastatic in vivo, but not normal epithelial cell lines, secrete
large amounts of extracellular NDPK-A/B resulting in primary
endothelial cell migration and proliferation. Next, we determined
the role of extracellular NDPK/ATP in the angiogenic pathway by
using pharmacological targets that effect the exogenous mitogenic
signalling from P2Y1R to mitogen-activated MAPK in endothelial
cells. Importantly, we demonstrate that inhibition of P2Y1R, the
tyrosine kinase phosphorylation activity of VEGFR-2, or the
tyrosine kinase phosphorylation activity of the proto-oncogene
non-receptor tyrosine kinase Src, prevents extracellular NDPK/
2-methylthio-ATP (2MeS-ATP) from inducing ERK/MAP activa-
tion and migration. Understanding the mechanism of the
sNDPK:P2Y signalling pathway may explain the failure of anti-
angiogenic monotherapy in certain patients, and defines a new
therapeutic target for future anti-angiogenesis treatment.
MATERIALS AND METHODS
Cell culture
Human breast cell lines HCC70, HCC202, HCC1143, MDA-MB-468,
MDA-MB-231, MDA-MB-435, MDA-MB-156, MDA-MB-361 and
MCF-7 as well as non-cancerous breast cells MCF-12 were obtained
from ATCC (Rockville, MD, USA) and grown as recommended by
the supplier. Primary cell lines of cloned human cord blood
endothelial colony forming cells (HEC) were purchased from
Dynacell Life Sciences (Spring House, PA, USA) and used
experimentally between passages 6 and 12. Human cord blood
endothelial colony forming cells were grown in endothelial growth
media-2 (EGM-2, Clonetics, Lonza, Basel, Switzerland) supplemented
with 10 or 2% fetal bovine serum (FBS) (v/v), 1% penicillin–
streptomycin (1000U penicillin/1mg streptomycin) and 0.2%
fungizone (Sigma, St Louis, MO, USA). All cell lines were grown
and maintained at 371C in a humidified 5% CO2 atmosphere.
Drugs and reagents
Yeast NDPK-B, MRS2179 (the P2Y1R antagonist), 2MeS-ATP (the
P2Y1R agonist) and EA/EGCG (NDPK inhibitors) were obtained
from Sigma. SU1498 (specific VEGFR-2 TRK inhibitor), suramin
(the P2Y non-specific antagonist) and PP2 (Src-Tyr-p inhibitor)
were obtained from Calbiochem (San Diego, CA, USA). Recombi-
nant Nm23-h2 (NDPK-B) proteins were obtained from Abnova
(Taipei City, Taiwan). PD098059 (ERK/MAPK inhibitor), VEGF165,
anti-phosphotyrosine p1175, anti-mitogen-activated protein kinase
pERK1/2 and mouse anti-MAPK (Erk1/2) were obtained from Cell
Signaling Technology (Beverly, MA, USA) and mouse anti-GAPDH
was from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Preparation of sNDPK
All breast carcinoma cell lines and MCF-12 were grown to 80%
confluence in T-150 tissue culture flasks, washed three times
with PBS and conditioned media collected and concentrated
as previously described (Rumjahn et al, 2007). Briefly, the
extracellular fluid was concentrated for 30min at 41C and
centrifuged at 2000g using Amicon Ultra-15 10kDa centrifugal
filters (Millipore Corporation, Bedford, MA, USA). The concen-
trated conditioned fluid was analysed for sNDPK-B protein by
immunoblotting and enzyme-linked immunosorbent assay (ELI-
SA) and ATP production was compared with the activity of
purified yeast NDPK-B. Human NDPK-B and yeast NDPK share
59% sequence identity at the protein level. Nucleoside diphosphate
kinase domains are present in a large family of structurally and
functionally conserved proteins from bacteria to humans that
generally catalyse the transfer of g-phosphates from an NTP such
as GTP, to an NDP acceptor (e.g., ADP). Human NDPK-B contains
152 amino acids; the active site phosphohistidine intermediate is at
residue 118. Yeast NDPK contains 153 amino acids; the active site of
phosphohistidine intermediate is at residue 119 and the enzymatic
site is identical to the human enzyme. While human NDPK-A and -B
share 88% sequence identity at the protein level; the active sites
and binding sites of these two isoforms are identical.
Transphosphorylation activity
The conversion of ADP to ATP using GTP as the phosphoryl donor
was quantified using the luciferin-luciferase ATP assay as
previously described (Buxton et al, 2001). Briefly, partially purified
sNDPK from the panel of breast cell lines and purified yeast
NDPK-B (Sigma) employed as a positive control were incubated
for 2min with GTP (300mM) as a phosphoryl donor and ADP
(30mM) as substrate. An equal volume of luciferin-luciferase ATP
detection buffer (Sigma) was added and a single measurement of
luminescence was recorded 10s later on a Luminoskan lumin-
ometer (model RS, Labsystems, Helsinki, Finland). Relative
luminescence units were adjusted for background and ATP
conversion was measured against a standard curve, which was
linear over three orders of magnitude.
Indirect ELISA
Human sNDPK was detected by ELISA. Ninety-six well plates
(Corning, Lowell, MA, USA) were coated with recombinant Nm23-
h2 (NDPK-B) protein as standard sample (Abnova), or serum test
proteins (experimental). Standard NDPK-B samples were em-
ployed over a range from 0.06 to 200ngml
 1 in phosphate-
buffered saline (containing 0.05% sodium azide); 50ml aliquots
were added to wells and the plate incubated for 2h at room
temperature (RT) and then overnight at 41C on a slow shaker.
Blocking buffer (100ml) containing 5% BSA and Tween-20 (0.05%)
in phosphate-buffered saline (PBST 0.05%) was added and
incubated for 1.5h at RT. Plates were then washed once with
150ml of PBST, incubated with primary mouse anti-nm23-H2
(NDPK-B) antibody (Abnova) diluted with PBST buffer containing
1m M EDTA and 0.25% BSA (100ml) for 2h at 371C with slow
rocking, and then washed three times with 150ml PBST. Plates were
incubated with rabbit anti-mouse IgG horseradish peroxidase
(HRP)-conjugate (Southern Biotech, Birmingham, AL, USA) for
2h at 371C with slow rocking and washed three times with PBST.
Plates were developed by addition of 100ml of o-phenylenediamine
dihydrochloride substrate (Sigma) and absorbance measured at
490nm using a microplate reader.
Immunoblotting of human sNDPK from breast cancer cell lines
To detect human sNDPK from conditioned fluid, the secreted
proteins were resolved on SDS–PAGE gels and transferred onto
nitrocellulose membranes and incubated at 41C overnight with
anti-NDPK-B mouse pAB (Abnova). Then, membranes were
incubated with secondary antibodies conjugated to Alexa Fluor
680 (Invitrogen, Carlsbad, CA, USA) in 1:1 Odyssey blocking
buffer (LI-COR Biosciences, Lincoln, NE, USA) and PBS with 0.1%
Tween-20 (v/v). Bands were visualised using the Odyssey Infrared
Imaging System (V2.04, LI-COR, Lincoln, NE, USA).
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Human cord blood endothelial colony forming cells were cultured
to B75% confluence in EGM-2 with 10% FBS on 100mm
2 dishes
and then switched to basal media (EBM-2) without growth factors
supplemented with 2% FBS for 24h. For combination treatment,
HEC were pretreated with antagonists for 20min before stimula-
tion with agonists for another 10min at 371C. Antagonists were
employed at concentrations chosen to provide maximal inhibition
of the known target. PD098059, 50mM (IC50¼2 10
 6 M; Alessi
et al, 1995), SU1498, 50mM (IC50¼7 10
7 M; Arbiser et al, 2000;
Rollin et al, 2004), PP2, 100nM (IC50¼100nM; Hanke et al, 1996;
Karni et al, 2003), MRS2179, 10mM (KB¼100nM; Boyer et al, 1998;
Baurand et al, 2001; Kaiser and Buxton, 2001, 2002) and suramin,
100mM (Beindl et al, 1996). The agonists employed were
100ngml
 1 VEGF, 10mM 2MeS-ATP and 10 units of yeast
NDPK-B (1unit¼0.76mg of NDPK-B converts 43.78mmoles of
ADP to ATP per min at 301C). P2Y1 receptors are maximally
stimulated by 10mM 2MeS-ATP (Ralevic and Burnstock, 1998;
Rumjahn et al, 2007). The medium was removed and the plates
rinsed twice in ice-cold PBS containing 0.5mM Na3VO4 and
suspended in lysis buffer containing 20mM Tris HCl pH 8, 150mM
NaCl, 10% glycerol, 1% Triton X-100 or Nonidet P-40 (NP-40),
1m M EGTA, 2.5mM sodium pyrophosphate, 1mM Na3VO4,1 m M
NaF and 1% Halt protease inhibitor (Pierce Biotechnology,
Rockford, IL, USA). Adherent cells were scraped from the plates
with a plastic cell scraper, collected in centrifuge tubes and
incubated at 41C on a rocker for 15min. The cell lysate was
centrifuged at 10000g at 41C for 30min, and supernatant protein
concentration determined by Lowry assay. Proteins were resolved
on SDS–PAGE gels and transferred onto nitrocellulose membranes
and incubated at 41C overnight with either rabbit anti-phospho-
tyrosine p1175 or rabbit anti-mitogen-activated protein kinase
pERK1/2. To detect total protein expression, membranes were
incubated at 41C overnight with mouse anti-MAPK (Erk1/2), mouse
anti-GAPDH or mouse anti-VEGFR-2. Then, all of the proteins
were incubated with secondary antibodies conjugated to either
Alexa Fluor 680 or Alexa Fluor 800 fluorescent dye (Invitrogen).
Bands were visualised using an Odyssey Infrared Imaging System
(V2.04).
Endothelial cell immunofluorescence assay
Human cord blood endothelial colony forming cells (5 10
3) were
plated in each well of an 8-well plate, grown to 75% confluence and
incubated with EBM containing 2% FBS for 24h before stimulation
with antagonists for 20min followed by agonist for another 10min
as described above. Each chamber was washed twice with sterile
cold PBS and monolayers fixed with 4% paraformaldehyde in PBS
for 15min at RT. Each chamber was washed three times for 5min
with PBS, blocked (0.25% Triton-X, 5% donkey serum) for 60min
and then incubated with primary anti-p-ERK1/2 antibody contain-
ing 10% BSA and 0.25% Triton-X overnight at 41C. Plates were
then rinsed four times for 5min in 1  PBS–0.1% Tween (PBST)
and incubated in fluorochrome-conjugated secondary antibody
(donkey anti-rabbit Alexa 488) for 1h at 41C in the dark. Plates
were subsequently washed with PBST four times for 5min. The
cells were stained with DAPI for 10min at 41C to reveal nuclei. The
slides were washed three times for 5min each in PBST and slide
mounting solution was added and a coverslip was placed on top of
the sections. Cells were viewed and imaged using the Olympus
FluoView FV1000 confocal scanning microscope (Olympus, Center
Valley, PA, USA).
Endothelial cell proliferation assay
Human cord blood endothelial colony forming cells (7 10
3) were
seeded on 24-well plates, grown to 70% confluence, shifted to
EBM-2 containing 2% FBS for 24h and then treated with either
10mM ellagic acid (EA), 10mM epigallocatechin gallate (EGCG) with
or without 2.5, 5, 10 or 20 units of NDPK-B (1unit¼0.76mgo f
NDPK-B to convert 43.78mmoles of ATP per min) or 100ngml
 1
VEGF (positive control) for 24h. Cells were washed once with PBS
and removed with trypsin (0.25%, 5min) and counted using a
Coulter cell counter (Beckman Coulter, Miami, FL, USA). Potential
toxicity of EA was tested in HEC grown in a 48-well plate to 75%
confluence with 10% FBS EGM media. The cells were grown in
EBM-2 media containing 2% FBS for 24h and then incubated with
10mM EA in 2% FBS EBM-2 media for 24h. In some cultures, the
medium containing 10mM EA was removed and the cells were
washed with PBS and fixed with the Diff-quick Stain Kit
(Polysciences, Warrington, PA, USA); in other cultures, the
medium containing 10mM EA was removed, the cells were washed
with 2% FBS EBM followed by addition of EGM containing 10%
FBS and cultures incubated for another 24h. Cells were then
washed with PBS and fixed with the Diff-quick Stain Kit and effects
of EA treatment determined by microscopy.
Endothelial cell migration assay
The effects of NDPK-B, P2Y1R agonist and antagonist, and Src and
VEGF antagonist on HEC migration were determined using a
modified Boyden chamber assay. Human cord blood endothelial
colony forming cells were cultured to B75% confluence on T-150
flasks and then switched to basal media (EBM-2) without growth
factors supplemented with 2% FBS for 24h. The serum-starved
human endothelial cells (2.5 10
5) were washed with PBS and then
seeded onto the upper side of a Transwell insert (Corning, Lowell,
MA, USA) membrane coated with a type-I rat-tail collagen
(0.9mgml
 1) and grown to 75% confluence. The agonist test
compounds (100ngml
 1 VEGF, 10mM 2MeS-ATP, 10 units NDPK-B,
GTP/ADP alone; or 5–20 units NDPK-B with GTP/ADP) were
added to the lower chamber, and antagonist compounds (10mM
MRS2179, 50mM SU1498 and 100nM PP2) were added to the upper
chamber. Plates were then incubated for 24h at 371C, 5% CO2 in a
humidified incubator. Following treatments, membranes were
removed, residual cells in the upper chamber were scraped away,
and the membrane stained with Diff-Quick solution (Dade
Behring, Newark, DE, USA). Quantification was performed by
counting dark blue nuclei in five contiguous microscopic fields
( 60, centre, up, down, left and right) generating mean±s.e.m.
cells per field. Micrographs were obtained at  10 magnification.
Statistical analyses
Graphs were prepared using Prism Graphing Software (V5;
GraphPad Software, San Diego, CA, USA) and statistical analyses
were performed using InStat Statistical Software (V3.0; GraphPad
Software). All experiments were tested for statistical significance
using ANOVA and a Pp0.05 was considered significant. Data
points and error bars represent mean values±s.e.m.
RESULTS
Human breast carcinoma cell lines secrete human NDPK-B
We have shown previously that the human breast carcinoma
cell line MDA-MB-435 secretes NDPK in vitro (Anzinger et al,
2001). The notion that NDPK secretion by these cells represented a
unique adaptation to culture, a feature of this cell line alone,
or the result of potential misidentification of the cells’ origins
(Ross et al, 2000) undermined the hypothesis that NDPK
secretion is a fundamental feature of transformed breast cells.
We sought to further our hypothesis by examining additional
cell lines derived from women with metastatic disease (Table 1)
and known to be metastatic in murine models of breast cancer
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sin vivo for extracellular NDPK activity that could support breast
cell angiogenesis. western blot studies (Figure 1A; Table 1)
revealed that breast cancer cell lines HCC70, HCC202, HCC1143,
MDA-MB-468, MDA-MB-231, MDA-MB-435, MDA-MB-156,
MDA-MB-361 and MCF-7 secreted shNDPK-A/B while we
were able to detect only insignificant amounts of shNDPK from
MCF-12 (a normal breast epithelial cell line) and detected no
activity.
Table 1 Breast cell NDPK-secretion correlates with cancerous origin
Cell line ATCC # Metastatic ER
+ Her2
+ shNDPK-B secretion
Cell line grown in culture
HCC70 CRL-2315 Yes-DC-primary Yes No Yes [++]
HCC202 CRL-2316 Yes-DC-primary No Yes Yes [++]
MDA-MB-468 HTB-132 Yes-AC-plural effusion No Yes Yes [++}
MDA-MB-361 HTB-27 Yes-AC-brain Yes Yes Yes [+]
MDA-MB-157 HTB-24 Yes-MC-plural effusion No unk Yes [+]
MDA-MB-435S
a HTB-129 Yes-DC-plural effusion No Yes Yes [+++]
MDA-MB-231 HTB-26 Yes-AC-plural effusion No No Yes [+++]
HCC1143 CRL-2321 Yes-DC-plural effusion No No Yes [+++]
MCF7 HTB-22 Yes-AC-plural effusion Yes Yes Yes [+++]
MCF-12A CRL-10782 No-normal mammary epithelium (immortal) Yes No No [ ]
MCF-10A CRL-10317 No-fibrocystic disease, epithelium No No No [ ]
Mice Cells implanted Location of implant Number
implanted
Time after
implant
Serum NDPK
(ngml
 1)
Control Tumours
NDPK measured in vivo
SCID MDA-MB-231-Luc+ 2.5 10
6 Mammary fat 6 4 Weeks 27.8 260.9
10 8 Weeks 26.5 250.0
Abbreviations: AC¼adenocarcinoma; DC¼ductal carcinoma; ER¼estrogen receptor; MC¼medullar carcinoma; NDPK¼nucleoside diphosphate kinase; unk¼unknown.
aGene expression analysis of MDA-MB-435S produced microarrays in which these cells clustered with cell lines of melanoma origin instead of breast (Rae et al, 2004).
[+]Positivity related to control using purified yeast NDPK-B (57.6±3.8mmoles ATP per mg per min) under Vmax conditions as [++].
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Figure 1 Detection of human NDPK-A/B protein secreted by breast cancer cell lines. Conditioned media from transformed and normal breast cell lines
was collected after 1.5h and concentrated as described in the text. (A) sNDPK-A/B protein was detected by western blot following separation of 25mgo f
total protein. (B) The concentration of sNDPK-A/B in conditioned media was quantified by ELSA assay. (C) Breast carcinoma cell lines secreted highly
significant amounts of sNDPK. Data are mean±s.e.m., n¼3. (D) Transphosphorylase activity was measured as ATP production in the luciferin-luciferase
assay under Vmax conditions (GTP 300mM, ADP 30mM). Yeast NDPK-B was employed as a positive control. Values, arrayed from high to low for comparison,
are expressed as mmoles ATP produced per mg protein per min. Data are mean±s.e.m., n¼3 and are all highly significant compared with zero addition
control.
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secreted human NDPK-A/B, which we employed to quantify
sNDPK in conditioned medium from breast carcinoma cell lines.
We found that breast carcinoma cell lines HCC70, HCC202,
HCC1143, MDA-MB-468, MDA-MB-231, MDA-MB-435, MDA-MB-
156, MDA-MB-361 and MCF-7 secreted significant amounts of
sNDPK-A/B (187.8, 737.5, 243.0, 198.7, 275.6, 278.1, 221.9, 343.5
and 339.7ngml
 1, respectively; Figures 1B and C), while none was
detected in conditioned media from MCF-12 cells.
sNDPK-B from breast cancer cell lines induces
phosphorylation activity
We utilised a transphosphorylase assay to measure the ATP
generating activity of sNDPK collected from the conditioned
medium of 11 cell lines and compared it with the activity of
purified yeast NDPK-B (Figure 1D). The assay was performed with
GTP (phosphoryl donor), ADP (phosphoryl acceptor) and breast
carcinoma cell conditioned medium or purified yeast NDPK-B
under Vmax conditions. Normal breast cells did not express extra-
cellular NDPK activity, while ATP production from cancerous
breast cell lines MDA-MB-231, MDA-MB-435, MCF-7, HCC1143,
MDA-MB-468, HCC202, HCC70, MDA-MB-156, MDA-MB-361 and
yeast NDPK-B (57.6mmol ATP per mg protein per min) supported
significant ATP production ranging from 154.4 to 25.58mmol ATP per
mg protein per min (Figure 1D). Cells that are known to form
metastases in vivo vs those considered non-cancerous, confirmed that
cells derived from women with metastatic disease secrete sNDPK
(Table 1). Results were correlated with the activity of purified yeast
NDPK-B and did not appear to correlate with expression of oestrogen
receptor, or expression of the Her2 protein.
Stimulation of P2Y receptors on HEC by NDPK and
2MeS-ATP induces VEGFR-2 activation
Extracellular NDPK activity elevates ATP levels and activates
endothelial P2Y receptors which in turn transactivate VEGFR-2,
inducing the phosphorylation of VEGFR-2 Tyr-1175 (Rumjahn
et al, 2009); an accepted indicator of the dimerisation and
activation of VEGFR-2. Addition of VEGF165 (100ngml
 1)t o
HEC cultures for 10min led to VEGFR-2 Tyr-1175 phosphorylation
compared with control cells receiving buffer alone (Figure 2A,
lanes 1 and 2). The NDPK’s enzymatic activity functions as an
NDPK (Postel, 2003) regenerating ATP levels by covalently
transferring the g-phosphate from an NTP such as GTP to an
NDP acceptor (e.g., ADP). We detected intense tyrosine 1175
phosphorylation of VEGFR-2 with addition of 10 units of NDPK in
the presence of substrate and phosphoryl donor (Figure 2A,
lane 5). Partial activation of VEGFR-2 (Tyr-1175 phosphorylation)
by NDPK in the absence of exogenous GTP/ADP is consistent with
the secretion of NDPK (Figure 2A, lane 3) as a phosphoryl-protein
able to support one round of endogenous adenine trinucleotide
formation (Anzinger et al, 2001). Our earlier work demonstrated
that the catechins EGCG and EA inhibit cancer cell-secreted NDPK
transphosphorylase activity (Rumjahn et al, 2007; Buxton, 2008).
Ellagic acid is a more potent NDPK inhibitor than other known
nucleoside analogues. Pretreatment of HEC cultures with EA
(10mM) with and without NDPK-B (10 units) plus GTP/ADP
diminished VEGFR-2 phosphorylation down to control levels
(Figure 2A, lanes 6 and 7).
To further define the pathway mediating the effect of NDPK on
VEGFR-2, we hypothesised that NDPK-regenerated ATP activates
the endothelial purinergic nucleotide receptor (P2Y1R) resulting in
Src phosphorylation which in turn phosphorylates VEGFR-2.
Addition of the P2Y1R-specific agonist 2MeS-ATP led to VEGFR-2
Tyr-1175 phosphorylation (Figure 2B, lane 2) that was blocked by
pretreatment of cells with P2Y1R, Src and VEGFR-2 selective
antagonists lanes 3, 5 and 8, respectively (Figure 2B). Next, we
compared the mechanism of P2Y1 mediated VEGFR-2 activation vs
VEGF165 stimulation (100ngml
 1) with and without the specific
VEGFR-2 TRK inhibitor SU1498 employed as negative control.
VEGF165 induced high VEGFR-2 phosphorylation levels and this
activation was inhibited significantly by SU1498 (Figure 2B, lanes 1
and 7). MRS2179 (10mM) did not prevent the effect of VEGF165
(Figure 2B, lane 4). The Src inhibitor PP2 (100nM) reduced, but did
not block the effect of VEGF165 (Figure 2B, lane 6).
Extracellular NDPK induces endothelial Erk1/2
phosphorylation
Erk1/2 phosphorylation via the Ras-RAF-Erk pathway induces cell
proliferation contributing to the activation of angiogenesis and
metastatic tumour growth. We hypothesised that extracellular
NDPK-B induces exogenous mitogenic signalling from endothelial
P2Y1R to MAPK. Stimulation of HEC with NDPK-B in the presence
MW VEGF CON NDPK-B G/A NDPK-B+G/A NDPK+EA EA
VEGFR2-
Tyr1175
VEGFR2-
Try1175
GAPDH
VEGFR2
9 8 7 6 5 4 3 2 1
7 6 5 4 3 2 1 Lane:
Lane:
MW VEGF 2MeS-ATP
2MeS-ATP
MRS
2MeS-ATP
PP2
2MeS-ATP
SU CON
VEGF
PP2
VEGF
SU
VEGF
MRS
37 kDa
250 kDa
250 kDa
250 kDa
Figure 2 Extracellular NDPK-B and 2MeS-ATP activate VEGFR-2. Western blots carried out for the detection of activated VEGFR-2. HEC were
maintained in low serum medium containing 2% FBS for 24h before pretreatment with antagonoists followed by agonists. VEGF (100ngml
 1, 10min)
employed as a positive control led to the phosphorylation of VEGFR-2 on tyrosine-1175 as expected (A and B). (A) Phosphorylated VEGFR-2 with loading
control. (B) Tyr-1175 phosphorylation of VEGFR-2 and VEGFR-2 protein was blotted as a loading control. Data are representative of three experiments
performed in duplicate.
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sof phosphoryl donor and acceptor produced high Erk1/2
phosphorylation (Figure 3A, lanes 2 and 7, B and C). With
addition of NDPK-B or GTP/ADP alone, Erk1/2 phosphorylation
was reduced by 60% compared with maximum stimulation
(Figure 3B), indicating that they produced partial activation of
Erk1/2 consistent with sub-maximal P2Y stimulation. The effect of
NDPK-B was inhibited by 10mM EA (Figure 3A, lane 5) which
diminished Erk1/2 phosphorylation back to near control levels
(Figure 3). VEGF165 was employed as positive control and gave a
11-fold increase above the negative control (data not shown).
Suramin (100mM), a non-specific endothelial P2Y receptor
inhibitor (Beindl et al, 1996), blocked 70% of the effect of 10
units NDPK-B plus donor/acceptor (Figure 3). Measurement of
Erk1/2 phosphorylation by immunofluorescence confirmed that
extracellular NDPK-B induced Erk1/2 phosphorylation, which was
inhibited by the NDPK transphosphorylation inhibitor (EA) and
non-specific P2Y receptor inhibitor suramin (Figure 3C).
Activated P2Y1R induces Erk phosphorylation
To further assess the potential mechanism of exogenous mitogenic
signalling from P2Y1R to mitogen-activated MAPK in endothelial
angiogenesis, we determined the effect of P2Y1R (MRS2179),
Src (PP2), VEGFR-2 (SU1498) and MEK (PD98059) antagonists on
nucleotide signalling. The relative magnitude of the effect of Erk1/2
MAPK in mediating the actions of the endothelial nucleotide
receptors can be seen when comparing the effect of the MAPK
inhibitor PD98059 on the activation of Erk1/2 when HEC are
stimulated by either 10mM 2MeS-ATP (Figures 4A and C) or
100ngml
 1 VEGF165 (Figures 4B and C). In both cases, the agonist
effects are completely blocked by PD98059. P2Y1R activation by
2MeS-ATP induced Erk1/2 phosphorylation that was inhibited by
MRS2179 (87.5%), PP2 (77.5%), SU1498 (73.7%) or PD98059
(90%), respectively (Figure 4A). VEGF165-mediated Erk1/2
phosphorylation was inhibited only 33% by MRS2179
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Figure 3 Extracellular NDPK-B induces HEC Erk1/2 phosphorylation. HEC were maintained in low serum medium containing 2% FBS for 24h before
pretreatment with antagonists followed by agonists. (A) Representative western blots showing both Erk and phospho-Erk (pErk1/2). (B) Average data from
multiple experiments. All treatments gave significantly lower pErk1/2 (Po0.001) compared with addition of NDPK-B in the presence of phosphoryl donor
and acceptor. Data are mean±s.e.m. normalised to total Erk expression by densitometry, n¼3. (C) Representative confocal images of pErk fluorescence in
HEC stimulated as shown (control 0.01% DMSO). (Bar¼20mm).
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s(Figure 4B). Our western blot and immunofluorescence results
indicate that 100nM PP2 (Figures 4B and C) has no effect on
VEGF165-stimulated Erk1/2 phosphorylation. SU1498 inhibited
VEGFR-2 phosphorylation (68%). The ability of the VEGFR-2
antagonist SU1498 (50mM) to prevent Erk1/2 activation by either
VEGFR-2 or P2Y1 receptor stimulation demonstrates that P2Y1
endothelial receptors signal through VEGFR-2 (Figure 4).
Effects of NDPK-B on endothelial cell proliferation
Secreted NDPK-B induces angiogenesis as measured by endothelial
cell tubule-like formation (Rumjahn et al, 2007). Here, we further
investigated the role of NDPK-B in endothelial angiogenesis. We
hypothesised that the activation of P2Y1R by extracellular NDPK-B
would promote the growth of endothelial cells in vitro, and that
inhibiting the function of NDPK-B would reduce endothelial cell
proliferation. Human cord blood endothelial colony forming cells
were stimulated for 24h with 1–100ng/ml VEGF (positive control)
or 0.3–20 units of NDPK-B. Extracellular NDPK-B was as effective
as VEGF in stimulating HEC proliferation (Figures 5A and B) over
the 24-h period. The concentration range of NDPK employed here
(0.3–30units¼0.5–500ngml
 1) correlates well with the activity
of sNDPK measured in breast cancer cell conditioned media (Ave.
272ngml
 1). If the effect of NDPK-B relies on ATP generation,
catechin compounds known to inhibit NDPK activity would
prevent NDPK effects on cell proliferation (Figure 5C). Ellagic
acid was more effective than EGCG in inhibiting cell growth
consistent with its effect as an NDPK inhibitor (Buxton, 2008) and
blocker of the effect of NDPK to promote angiogenesis (Rumjahn
et al, 2007). To examine the effect of extracellular NDPK-B protein
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Figure 4 Erk1/2 phosphorylation by P2Y1R agonist or VEGF. HEC were maintained in low serum medium containing 2% FBS for 24h before treatment
with (A) 2MeS-ATP (10mM)o r( B) VEGF (100ngml
 1) following antagonist pretreatment. (A) 2MeS-ATP produced significant activation of Erk1/2 that was
significantly blocked (Po0.001) by MRS2179, PP2, SU1498 or PD89059. (B) VEGF activation of Erk1/2 showed partial significant sensitivity to MRS2179, but
insensitivity to PP2. Control (CONT) received 0.01% DMSO as a drug dilution control. (A and B) Data are mean±s.e.m. normalised to total Erk expression
by densitometry; one-fold¼non-stimulated control, n¼3. (C) Imaging of phospho-Erk1/2; cells were pretreated with 10mM MRS2179, 100nM PP2 or 50mM
SU1498. Images are representative of multiple micrographs aquired from three experiemnts; bar¼20mm.
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sand its inhibitors in primary HEC proliferation, HEC were
incubated with various concentrations of EA and EGCG
(1–30mM) with and without 20 units of NDPK-B protein for 24h
(Figures 5D and E). The activity of NDPK-B to induce angiogenesis
via cell proliferation was diminished to the basal level in the
presence of 10mM EA (Figure 5D). The results indicate that 10 and
30mM EGCG inhibit HEC proliferation (Figures 5C and E), but
when combined with 20 units of extracellular NDPK-B, EGCG
inhibition is trivial (Figure 5E). Cells were also treated with various
amounts of NDPK-B (0, 5, 10 and 20 units) in the presence of
EGCG or EA (10 or 30mM) (Figure 5F). The effects of EA and EGCG
were dose dependent (Figures 5D and E) and confirmed that EA is
more efficacious than EGCG in preventing NDPK-mediated cell
proliferation (Figures 5C–F). Control experiments confirmed that
EA was non-toxic to the cells and show that the drug acts in a
reversible manner (Figure 5G).
Extracellular NDPK-B induces ECFC migration
We determined the effect of P2Y1R activation by extracellular
NDPK-B protein on HEC migration in vitro using a modified
Boyden chamber assay. VEGF was employed as positive control.
The NDPK-B protein was added at various concentrations (5, 10
and 20 units; Figure 6) and cells stimulated for 24h. Migration
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Figure 5 Extracellular NDPK-B stimulates HEC growth and NDPK-B transphosphorylation inhibitors block the growth stimulatory effects of NDPK-B.
HEC were maintained in low serum medium containing 2% FBS for 24h before treatment with increasing concentrations of (A) VEGF, (B) NDPK-B or
(C) catechin (EA/EGCG) for an additional 24h in 2% FBS containing 0.01% (v/v) DMSO diluent in EBM media. (A) VEGF protein and (B) NDPK-B protein
(C) treatment of cells with the NDPK-B antagonist catechins EA or EGCG at increasing concentrations. (D) Twenty units of NDPK-B in combination with
increasing concentrations of EA. (E) Twenty units of NDPK-B in combination with increasing concentrations of EGCG. (F) Increasing concentrations of
NDPK-B in combination with 10 or 30mM concentrations of EGCG or EA. (G) The drug is removed and cells are returned to growth conditions. Data are
mean±s.e.m., n¼3, *Po0.05, ***Po0.001 vs no drug,
þPo0.05 vs 10mM EA. Micrographs are representative of results, n¼4.
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sstimulated by VEGF (100ngml
 1) was matched by treatment with
20 units of NDPK-B in the presence of phosphoryl donor and
acceptor (GTP, 300mM; ADP, 30mM). The effect of NDPK-B was
dose dependent (Figure 6). The phosphoryl donor acceptor mix
(GTPþADP) and NDPK-B alone had an effect vs control (no
addition) consistent with the notion that ADP alone can activate
P2Y receptors and that NDPK-B alone has been shown to stimulate
angiogenesis (Rumjahn et al, 2007).
We determined the effect of extracellular NDPK-B vs specific
P2Y1 activation by 2MeS-ATP on endothelial cell migration using a
modified Boyden chamber assay. Activation of P2Y1R by 2MeS-
ATP or extracellular NDPK-B is as effective as VEGF in stimulating
endothelial cell migration (Figure 7C). Stimulation of HEC by
either 10mM 2MeS-ATP or 10 units of NDPK-B in the presence of
GTP and ADP induced similar levels of migration (B7-fold above
the negative control, Figure 7). Human cord blood endothelial
colony forming cells migration stimulated by 2MeS-ATP or
NDPK-B plus GTP/ADP was significantly reduced by the P2Y1R
antagonist MRS2179 or the Src inhibitor PP2 and to the same
extent, while the VEGFR-2 antagonist SU1498 (Figure 7) was far
more effective blocking essentially all of the stimulation produced
by either agonist.
DISCUSSION
ATP is released by endothelial cells under sheer stress (Milner
et al, 1996) and hypoxic conditions and is both vasodilatory (Yang
et al, 1994; Buxton et al, 2001) and pro-angiogenic (Gerasimovs-
kaya et al, 2008). Here, we offer evidence of the pathologic ability
of breast tumour cells to stimulate endothelial angiogenesis. We
found that a panel of cancerous human breast cell lines,
representing many of the models used in recent years by
investigators studying the metastatic process, secreted both
NDPK-A/B while normal cultured breast cell lines do not. We
detected an B19-kDa band (NDPK-A) and B17-kDa band
(NDPK-B) by western blot and quantified them by ELISA (Figures
1A and C). We showed that the ELISA developed with anti-NDPK-B
antibody also recognises the NDPK-A protein (Figure 1B). Nucleo-
side diphosphate kinase-A has been found in neuroblastoma
(Okabe-Kado et al, 2005b), B and T-cell lymphoma (Niitsu et al,
2003, 2004), haematological malignancies (Okabe-Kado, 2002) and
leukaemia (Niitsu et al, 2000; Okabe-Kado et al, 2002) where it
induces cell proliferation (Okabe-Kado et al, 2009b) and activates
cytokine production (Okabe-Kado et al, 2009a).
Our results demonstrated conclusively that the effects of
endothelial P2Y1 receptor stimulation result in the activation of
VEGFR-2 in the absence of VEGF. This striking result is borne out
by the ability of the VEGFR-2 antagonist SU1498 to block the effect
of P2Y receptor agonist to cause VEGFR-2 phosphorylation
(Figure 2B). The ability of breast tumour cells to orchestrate
angiogenesis is provided for by their ability to secrete NDPK,
which can result in transactivation of the VEGF receptor-2 even in
the absence of VEGF (Figure 2A). The enhancement of the effect of
NDPK-B when a phosphoryl donor and substrate acceptor are
present, together with the ability of the NDPK inhibitor EA to
block VEGFR-2 phosphorylation establishes the effect of NDPK-B
as acting through P2Y receptor stimulation. The ability of 2MeS-
ATP to mimic the effect of NDPK-B, and for both to be prevented
by the P2Y1R antagonist MRS2179 is convincing proof that NDPK-B
acts through P2Y1R activation in HEC. The fact that NDPK-B
activates its vascular endothelial receptor (P2Y receptor), which in
turn activates VEGFR-2 in the absence of VEGF (Figures 2 and 8)
offers the intriguing possibility that focusing on P2Y mechanisms
in angiogenesis might broaden the armamentarium in prevention
of breast cancer metastasis.
Endothelial cell VEGFR-2 activation by extracellular NDPK-B
results in Erk1/2 phosphorylation, which is prevented by EA, an
NDPK inhibitor, and suramin a non-specific P2YR antagonist
(Figure 3). Together, these results indicate that activation of P2Y
receptors by extracellular NDPK-B is crucial in the transactivation
of VEGFR-2 and subsequent downstream regulation of the
Raf-MEK-MAPK pathway (Figure 8).
The ability of the Src inhibitor PP2 to block both P2Y1R and
VEGF stimulation of VEGFR-2 phosphorylation (Figure 2B), while
having little effect on VEGF-stimulated Erk1/2 phosphorylation is
consistent with the notion that P2Y1R signals to activate VEGFR-2
via Src activation (Figure 4B). The ability of VEGF to activate
VEGFR-2 Tyr-1175 phosphorylation is, by contrast, a direct effect
of the growth factor to bind and activate its receptor (Figure 2B).
The contrast in the transactivation of VEGFR-2 by P2Y1R
activation vs VEGF activation can be seen in the ability of PP2
to block P2Y1R but not VEGF activation of VEGFR-2 (Figure 2B).
PP2 fails to prevent VEGF activation of Erk1/2 (Figure 4B),
0
VEGF
NDPK-B (20 U+G/A)
NDPK-B (10 U+G/A)
NDPK-B (5 U+G/A)
GTP/ADP
NDPK-B (10 U)
02468 1 0
Ø
246
Endothelial cell migration (fold control)
81 0
Figure 6 Extracellular NDPK-B stimulated HEC migration. HEC were
maintained in low serum medium for 24h. HEC growing on membrane
supports coated with collagen were stimulated from below for 24h with
VEGF (100ngml
 1) as positive control, or by increasing concentrations of
NDPK-B in the presence of GTP 300mM/ADP 30mM, control sets were
GTP/ADP, 10 units NDPK-B alone and negative control (Ø) in 2% FBS in
EBM media. Membranes were prepared and stained as described in the
text. Data are mean±s.e.m. in 3–5 experiments. Data are expressed as
fold control where 1¼no addition (Ø). All treatments produced significant
migration compared with control (Po0.03).
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sconfirming that Src does not phosphorylate Erk in human
endothelial cells.
We have previously shown that the activation of the P2Y1
receptor is crucial in the activation of tubule formation in
endothelial cells (Rumjahn et al, 2007). In this study, we were
particularly interested in examining the mechanisms of the P2Y1
receptor pathway with regard to transactivation of VEGFR-2
Tyr-1175, Erk1/2 activation, and functional determination of
cell growth and migration (Figures 5–7). The ability of VEGF
to stimulate endothelial cell growth is mimicked by NDPK-B in a
concentration-dependent manner (Figure 5). Endothelial cell pro-
liferation is prevented by EA and partially effected by EGCG, which
is consistent with the idea that these compounds block NDPK-B
activity. While EA treatment prevents endothelial proliferation
induced by NDPK-B, it is not cytotoxic and the cells recover
after removal of EA (Figure 5G). VEGF is known to promote
endothelial cell migration as well as cell proliferation. We examined
the effects of both NDPK-B and VEGF on endothelial cell migration
and found that 20 units of NDPK stimulated endothelial cell
migration that was equivalent to 100ng VEGF under the same
conditions and the effect of NDPK was concentration dependent
(Figure 6).
In examining the mechanism of action of sNDPK, it is
interesting to note that sNDPK is thought to bind to the high
molecular weight fragment of MUC-1 (Mahanta et al, 2008), also
shown to be present in the conditioned medium from breast
cancer cells in culture (Thathiah et al, 2003). The finding that
purified bovine NDPK binds to MUC-1 was seen as evidence for its
growth stimulatory properties in human embryonic stem cells
(Hikita et al, 2008). In the studies described here and elsewhere
(Buxton et al, 2010), NDPK is acting via P2Y receptor activation in
an ATP-dependent manner. While we do not rule out a role for the
MUC-1 protein in the breast cancer angiogenic process; indeed it
would mediate actions of NDPK acting directly and as such fits
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Figure 7 Antagonism of 2MeS-ATP or NDPK-B-mediated HEC migration is consistent with Src activation of VEGFR-2. HEC were seeded on the upper
surface of collagen-coated membranes as described in the text. (A) Ten units of NDPK-B added in the presence of phosphoryl donor and acceptor that
produced Vmax conditions for ATP production. (B). All antagonist treatments (A and B) produced highly significant blockade. (C) Micrographs
representative of the result in each experiment. Membranes were prepared and stained as described; migrated cells were counted and values expressed as
percentage of the maximum stimulation defined as VEGF-stimulated migration. Values are mean±s.e.m., n¼3–5 and all statistical comparisons of the
effects of inhibitors on stimulated migration (A and B) are significant at Po0.001.
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swith our overall hypothesis regarding the importance of sNDPK;
the effects of sNDPK we have measured are best explained by its
action as a generator of purinergic agonist. Future studies to link
MUC-1 and sNDPK and possibly the P2 receptor may further our
understanding of tumour cell-mediated angiogenesis.
The extracellular actions of purine nucleotides are known to be
important in bleeding disorders, hypertension, stroke and
osteoporosis, and it is also important for physiological functions
such as vasodilation, platelet aggregation, and neural and stem cell
proliferation. Here, we demonstrated that the P2Y1R regulates
endothelial migration following the action of soluble NDPK-B or
2MeS-ATP and that activation was blocked by the P2Y1R receptor
antagonist (MRS2179) as well as the Src kinase blocker PP2
(Figure 7). The Src family kinases are signalling enzymes that have
been recognised as cellular process regulators, and it is known that
Src has an important role in the promotion of endothelial
monolayer permeability (Hu et al, 2008) and in supporting FAK
signalling in VEGF-induced endothelial cell migration and survival
(Abu-Ghazaleh et al, 2001). The ability of the VEGFR-2 antagonist
SU1498 to block both NDPK-B and 2MeS-ATP effects on cell
migration confirmed that these effects are mediated by VEGFR-2
(Figure 7).
A role for nucleotides in the angiogenic process in this manner
suggests potential therapeutic targets that might help to control
latency. However, the mechanisms by which P2Y receptors
mediate vasodilation and anti-platelet aggregation (advantageous
to the transit of cancer cells to secondary sites), and tumour
angiogenesis remains to be defined in vivo. Because endothelial
P2Y1 receptors are thought to participate in transendothelial
migration (Sud’ina et al, 1998), we propose that, in addition to the
notion that tumour-secreted sNDPK promotes endothelial cell
growth and migration in support of angiogenesis at the metastatic
niche, release of sNDPK during early primary tumour development
can promote transendothelial cell migration and movement of cells
out of the breast to distant sites in the body (Figure 8).
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Figure 8 Endothelial nucleotide receptor signalling in tumour angiogenesis. VEGFR-2, the principle receptor on endothelium known to regulate
angiogenesis is activated by VEGF. We demonstrate here that the endothelial nucleotide P2Y receptor is an important angiogenesis regulator. In the tumour
micro-environment, tumour cells secrete sNDPK which generates ATP from ADP locally. ADP availability is predicted from necrosing cells and acts on the
endothelial nucleotide P2Y receptor to regulate blood flow and vascular permeability, which in turn enables the metastatic process. Our results reveal that
sNDPK release by breast tumour cells activates VEGFR-2 via P2Y1R stimulation. Inhibition of P2Y1R, Src and VEGFR-2 tyrosine kinase phosphorylation
prevents extracellular NDPK-B/2MeS-ATP from inducing Erk/MAPK activation and cell migration. Therefore, we propose that P2Y1R receptor activation
could be an early signal to activate growth of dormant metastases that do not themselves as yet secrete VEGF. Considerable focus should be placed on
nucleotide signalling in angiogenesis as this pathway may become a therapeutic target for tumour anti-angiogenesis in breast cancer.
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